�Curbing  the activity of a pith called "platelet-derived growth factor receptor A"  dramatically reduced aggressiveness of an often untreatable childhood muscle cancer in mice and cells, a young study from The  University  of Texas  Health  Science  Center  at San  Antonio  and partner institutions shows.
Research  sites included the UT  Health  Science  Center's  Greehey  Children's  Cancer  Research  Institute  (Greehey  CCRI)  and the university's departments of Cellular  and Structural  Biology,  Pediatrics,  Medicine,  and Epidemiology  and Biostatistics.  National  collaborators ar from the University  of Virginia,  Ohio  State  University,  the Columbus  Children's  Research  Institute,  and the Taussig  Cancer  Center  and Lerner  Research  Institute  at the Cleveland  Clinic.
The  work is reported in the to the highest degree recent online advance take of the journal Oncogene  (http://www.nature.com/onc/journal/vaop/ncurrent/abs/onc2008255a.html).
Difficult-to-treat  subtype
Childhood  muscle cancers, also called rhabdomyosarcomas, ar the most common diffuse tissue sarcomas of puerility. The  alveolar subtype is particularly difficult to regale because at diagnosis more than half of the children have lymph node involvement or distant metastasis (spread), the authors wrote.
"The  way this disease grows and spreads has perplexed clinicians and researchers for nearly 3 decades, during which clip the dreary outcome for metastatic alveolar rhabdomyosarcoma has remained essentially unchanged despite improvements in surgical technique, radiation delivery and chemotherapy," said coauthor Charles  Keller,  M.D.,  help professor of Cellular  and Structural  Biology  at the Greehey  CCRI.
The  cure rate for the metastatic form is estimated to be 20 pct or let down. Dr.  Keller  said the findings offer a promising avenue for improving that outcome. "A  therapeutic scheme for children with musculus cancer power be developed that would target this growth receptor and perhaps similar ones at the same fourth dimension," he aforesaid. "The  benefit to the patient is that such treatments ar clinically available today for adult cancer patients wHO have other diseases. Importantly,  too, the way these targeted therapies work is less toxic than chemotherapy."
Authentic  model
The  researchers studied genetically engineered mice with tumors that develop the mutations, and haunt metastases, inherent to alveolar rhabdomyosarcomas. Dr.  Keller  developed this specialized mouse neoplasm model spell training in the science lab of 2007 Nobel  Laureate  Mario  Capecchi,  Ph.D.,  at the University  of Utah.
In  the current study, assays performed in the Keller  laboratory by postdoctoral trainee Eri  Taniguchi,  Ph.D.,  showed that platelet-derived growth factor receptor A,  and deuce proteins that mediate its effects, were highly activated in both the elementary and metastatic tumors.
Using  trey different methods to dampen the platelet-derived growth factor receptor, the scientists celebrated significant simplification of neoplasm cell outgrowth both in the mice and in cell cultures.
"We  believe this clearly establishes platelet-derived maturation factor sensory receptor A  as a voltage future therapeutic target in alveolar rhabdomyosarcoma," Dr.  Keller  said.
NCI  ulysses S. Grant support
This  work is supported by a five year, $1.5 million duncan Grant recently awarded by the National  Cancer  Institute  (NCI)  to the Keller  testing ground, and it is likewise the base for the Greehey  CCRI's  forthcoming rank in the NCI's  Pediatric  Preclinical  Testing  Program.  Dr.  Keller  volition lead the Greehey  CCRI  Pediatric  Preclinical  Testing  Initiative.
One  tempering gene in the study is this determination: while two-thirds of the mice showed a response, one-third developed resistance to the therapy after two weeks. This  mimics opposition rates seen with adult cancers treated with a receptor inhibitor. Ongoing  studies at the Greehey  CCRI  now direct to watch how resistance can be overcome. "Moving  our results to the clinic will require close attention and further study of how tumors become resistant to this drug," Dr.  Keller  said.
Co-authors  from the UT  Health  Science  Center  are the trail author, Dr.  Taniguchi;  Koichi  Nishijo,  M.D.,  Ph.D.,  and Amanda  T.  McCleish,  all at the Greehey  CCRI;  Joel  E.  Michalek,  Ph.D.,  departments of Epidemiology  and Biostatistics  and Pediatrics;  Marcia  H.  Grayson  and Anthony  J.  Infante,  M.D.,  Ph.D.,  Pediatrics;  and Hanna  E.  Abboud,  M.D.,  the Jay  Stein  Professor  in Medicine/Nephrology.
Dr.  Keller  and other staff at the Greehey  CCRI  are members of the Cancer  Therapy  & Research  Center  at the UT  Health  Science  Center.
About  the UT  Health  Science  Center  San  Antonio
The  University  of Texas  Health  Science  Center  at San  Antonio  is the starring research institution in South  Texas  and one of the major health sciences universities in the universe. With  an operating budget of $576 million, the Health  Science  Center  is the tribal chief catalyst for the $15.3 one thousand million biosciences and health guardianship sector in San  Antonio's  economy. The  Health  Science  Center  has had an estimated $35 billion shock on the region since inception and has expanded to sextet campuses in San  Antonio,  Laredo,  Harlingen  and Edinburg.  More  than 23,000 graduates (physicians, dentists, nurses, scientists and allied health professionals) serve in their fields, including many in Texas.  Health  Science  Center  faculty ar international leadership in crab, cardiovascular disease, diabetes, ripening, stroke prevention, kidney disease, orthopaedics, inquiry imaging, graft surgery, psychological medicine and clinical neurosciences, hurting management, genetic science, nursing, allied health, dental medicine and many other fields. For  more information, inspect http://www.uthscsa.edu.
   
University  of Texas  Health  Science  Center  at San  Antonio
7703  Floyd  Curl  Dr.
San  Antonio,  TX  78229-3900
United  States
http://www.uthscsa.edu
More  info
Wednesday, 27 August 2008
Friday, 8 August 2008
Jessica Simpson sing about 'real' abuse
Jessica  Simpson  has made an honest confession in her new country music debut 'Do  You  Know?'.  In  a track from the record album Remember  That,  in which she claims that she talks from an real experience when she says "With  his hands or with his words/you don River"t deserve it". The  song is about pervert, it seems from the lyrics. The  singer most let the cat verboten of the bag when she was asked whether she had a first hand intervention of blackguard. She  said that the experience was not a joyous which is why she would not like to recall it merely she would suggest that anybody world Health Organization might be facing shout should run far aside from it 'along with their heart'. 
More information
More information
Subscribe to:
Comments (Atom)